시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 보고서(2025년)
Histone Deacetylase (HDAC) Inhibitors Global Market Report 2025
상품코드 : 1825762
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

히스톤 탈아세틸화효소(HDAC) 억제제 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 17억 6,000만 달러로 성장할 것이며, 연평균 7.4%의 성장률을 보일 것입니다. 예측 기간 동안의 성장 배경에는 신경퇴행성 질환의 유병률 증가, 암에 대한 인식 증가, 의약품 개발에 대한 투자 증가, 임상시험 수 증가, 맞춤형 의료의 채택 증가 등이 있습니다. 예측 기간의 주요 동향으로는 기술 발전, 맞춤형 의료, 암 면역 치료의 시너지 효과, 디지털 헬스 솔루션의 통합, 바이오인포매틱스 등을 꼽을 수 있습니다.

향후 5년간 7.4%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 스위스나 영국에서 개발된 히스톤 탈아세틸화효소(HDAC) 억제제(HDAC 억제제)의 가격을 급등시켜 암 치료 지연과 전문 약국 비용 상승을 초래하여 미국의 첨단 림프종 치료제의 채택을 방해할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

신경퇴행성 질환의 유병률 증가는 히스톤 탈아세틸화효소(HDAC) 억제제 시장의 성장을 견인할 것으로 예상됩니다. 신경퇴행성 질환은 뇌와 척수 신경세포의 퇴행이나 사멸이 진행되어 인지장애와 운동장애를 일으키는 질환입니다. 여기에는 아밀로이드 플라크와 타우의 엉킴으로 인한 기억 상실과 인지 기능 저하를 특징으로 하는 알츠하이머병과 같은 질환이 포함됩니다. 신경퇴행성 질환의 증가는 노화, 유전, 장수, 환경적 영향 등의 요인과 관련이 있습니다. HDAC 억제제는 유전자 발현을 조절하고 신경 보호 작용을 발휘하기 때문에 이들 질환의 잠재적 치료제로 연구되고 있습니다. 예를 들어, 2024년 8월 미국 연방정부 기관인 질병통제예방센터(CDC)는 현재 미국에서 약 670만 명의 노인이 알츠하이머병을 앓고 있으며, 2060년까지 그 수가 거의 두 배인 1,400만 명에 달할 것으로 예측했습니다. 그 결과, 신경퇴행성 질환의 발병률 증가가 HDAC 억제제 시장 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Histone deacetylase (HDAC) inhibitors are a category of compounds that inhibit the activity of histone deacetylase enzymes. These enzymes are responsible for the removal of acetyl groups from histone proteins, resulting in a more compact chromatin structure and decreased gene expression. By promoting hyperacetylation of histones, HDAC inhibitors generally lead to a more open chromatin structure, making DNA more accessible to transcription factors.

Histone deacetylase (HDAC) inhibitors are categorized into four main classes class I, class II, class III, and class IV HDACs. Class I HDACs primarily regulate gene expression by altering chromatin structure and are involved in numerous cellular processes. They are extensively researched for their potential use in treating cancer and other diseases. HDAC inhibitors can be administered orally or parenterally and are applied in fields such as oncology and neurology. They are utilized by various end users, including hospitals, academic and research institutes, and pharmaceutical companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The histone deacetylase (HDAC) inhibitors market research report is one of a series of new reports from The Business Research Company that provides histone deacetylase (HDAC) inhibitors market statistics, including histone deacetylase (HDAC) inhibitors industry global market size, regional shares, competitors with a histone deacetylase (HDAC) inhibitors market share, detailed histone deacetylase (HDAC) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the histone deacetylase (HDAC) inhibitors industry. This histone deacetylase (HDAC) inhibitors research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The histone deacetylase (hdac) inhibitors market size has grown strongly in recent years. It will grow from $1.23 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to a rise in funding for epigenetic research, rising prevalence of drug-resistant cancers, rise in healthcare expenditure, increasing utilization of HDAC inhibitors in veterinary medicine, and increasing investment in bioinformatics.

The histone deacetylase (hdac) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to the rising incidence of neurodegenerative disorders, growing awareness about cancer, rising investment in drug development, growing number of clinical trials, and increasing adoption of personalized medicine. Major trends in the forecast period include technological advancements, personalized medicine, cancer immunotherapy synergies, integration of digital health solutions, and bioinformatics.

The forecast of 7.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of cutting-edge lymphoma therapies by inflating prices of Histone Deacetylase (HDAC) Inhibitors(HDAC inhibitor) drugs developed in Switzerland and the UK, resulting in delayed oncology treatments and higher specialty pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of neurodegenerative disorders is expected to drive the growth of the histone deacetylase (HDAC) inhibitors market. Neurodegenerative disorders, which involve the progressive degeneration and death of neurons in the brain and spinal cord, result in cognitive and motor impairments. These include conditions like Alzheimer's disease, characterized by memory loss and cognitive decline due to amyloid plaques and tau tangles. The rise in neurodegenerative disorders is linked to factors such as aging, genetics, longevity, and environmental influences. HDAC inhibitors are being investigated as potential treatments for these disorders because of their ability to regulate gene expression and offer neuroprotective effects. For example, in August 2024, the Centers for Disease Control and Prevention (CDC), a US federal agency, reported that approximately 6.7 million older adults in the United States are currently living with Alzheimer's disease, a number projected to nearly double to 14 million by 2060. As a result, the growing incidence of neurodegenerative diseases is fueling the expansion of the HDAC inhibitors market.

Key players in the HDAC inhibitors market are concentrating on developing novel treatments, such as HDAC inhibitors for cancer therapy, to improve efficacy and minimize side effects. HDAC inhibitors are a class of drugs used in cancer therapy that work by blocking HDAC enzymes, which usually remove acetyl groups from histone proteins. This blockage results in increased acetylation of histones, altering chromatin structure and affecting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based firm specializing in pioneering cancer therapies, received new patents from the U.S. Patent and Trademark Office for HDAC inhibitors targeting cancer treatment. These new inhibitors are designed to target specific HDAC enzymes associated with cancer progression, aiming to disrupt abnormal gene expression linked to tumor development and spread. The patented compounds offer improved potency and selectivity, reducing off-target effects and enhancing safety for patients.

In June 2024, Italfarmaco SpA, a US-based pharmaceutical company, formed a partnership with Iktos SA for an undisclosed amount. This collaboration aims to accelerate drug discovery in non-oncological areas by utilizing AI to design advanced HDAC inhibitors. Iktos SA is a France-based technology company specializing in artificial intelligence solutions for medicinal chemistry and drug discovery.

Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the histone deacetylase (HDAC) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The histone deacetylase (HDAC) inhibitors market consists of sales of valproic acid, hydroxamic acids, cyclic peptides, short-chain fatty acids, and benzamides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Histone Deacetylase (HDAC) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on histone deacetylase (hdac) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for histone deacetylase (hdac) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The histone deacetylase (hdac) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Histone Deacetylase (HDAC) Inhibitors Market Characteristics

3. Histone Deacetylase (HDAC) Inhibitors Market Trends And Strategies

4. Histone Deacetylase (HDAC) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Histone Deacetylase (HDAC) Inhibitors Growth Analysis And Strategic Analysis Framework

6. Histone Deacetylase (HDAC) Inhibitors Market Segmentation

7. Histone Deacetylase (HDAC) Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market

9. China Histone Deacetylase (HDAC) Inhibitors Market

10. India Histone Deacetylase (HDAC) Inhibitors Market

11. Japan Histone Deacetylase (HDAC) Inhibitors Market

12. Australia Histone Deacetylase (HDAC) Inhibitors Market

13. Indonesia Histone Deacetylase (HDAC) Inhibitors Market

14. South Korea Histone Deacetylase (HDAC) Inhibitors Market

15. Western Europe Histone Deacetylase (HDAC) Inhibitors Market

16. UK Histone Deacetylase (HDAC) Inhibitors Market

17. Germany Histone Deacetylase (HDAC) Inhibitors Market

18. France Histone Deacetylase (HDAC) Inhibitors Market

19. Italy Histone Deacetylase (HDAC) Inhibitors Market

20. Spain Histone Deacetylase (HDAC) Inhibitors Market

21. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market

22. Russia Histone Deacetylase (HDAC) Inhibitors Market

23. North America Histone Deacetylase (HDAC) Inhibitors Market

24. USA Histone Deacetylase (HDAC) Inhibitors Market

25. Canada Histone Deacetylase (HDAC) Inhibitors Market

26. South America Histone Deacetylase (HDAC) Inhibitors Market

27. Brazil Histone Deacetylase (HDAC) Inhibitors Market

28. Middle East Histone Deacetylase (HDAC) Inhibitors Market

29. Africa Histone Deacetylase (HDAC) Inhibitors Market

30. Histone Deacetylase (HDAC) Inhibitors Market Competitive Landscape And Company Profiles

31. Histone Deacetylase (HDAC) Inhibitors Market Other Major And Innovative Companies

32. Global Histone Deacetylase (HDAC) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Histone Deacetylase (HDAC) Inhibitors Market

34. Recent Developments In The Histone Deacetylase (HDAC) Inhibitors Market

35. Histone Deacetylase (HDAC) Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기